Update on real-world use of facilitated subcutaneous immunoglobulin and immune globulin subcutaneous (human) 20% solution in patients with immunodeficiencies: poster extracts from the 19th Biennial Meeting of the European Society for Immunodeficiencies

Michael Borte; Colin Anderson-Smits; Corinna Hermann

doi:10.1080/1744666X.2021.1913122

Update on real-world use of facilitated subcutaneous immunoglobulin and immune globulin subcutaneous (human) 20% solution in patients with immunodeficiencies: poster extracts from the 19th Biennial Meeting of the European Society for Immunodeficiencies

Expert Rev Clin Immunol. 2021 Apr;17(sup1):7-8. doi: 10.1080/1744666X.2021.1913122. Epub 2021 May 26.

Authors

Michael Borte¹, Colin Anderson-Smits², Corinna Hermann³

Affiliations

¹ Hospital for Children and Adolescents, St. Georg Hospital; Academic Teaching Hospital of the University of Leipzig, Leipzig, Germany.
² Global Evidence and Outcomes, Shire Human Genetic Therapies, Inc., a Takeda Company, Cambridge, MA, USA.
³ Global Medical Affairs, Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria.

PMID: 33908818
DOI: 10.1080/1744666X.2021.1913122

Abstract

Immunoglobulin replacement therapy has been shown in clinical trials to be an important therapeutic option for reducing the incidence of serious bacterial infections and improving the quality of life in patients with primary and secondary immunodeficiencies (PID and SID, respectively). This article summarizes a poster series presented at the 19th Biennial Meeting of the European Society for Immunodeficiencies (October 14-17, 2020) further evaluating real-world usage and patient/physician experience with Immune Globulin Subcutaneous (Human) 20% Solution (Ig20Gly) in patients with PID and facilitated subcutaneous immunoglobulin (fSCIG) in patients with PID or SID.

Keywords: Ig20Gly; Primary immunodeficiency diseases; facilitated subcutaneous immunoglobulin; immunoglobulin replacement therapy; real-world evidence; secondary immunodeficiency diseases.